One Diagnosis, Different Diseases: Is TLR7/8 Inhibition the Future of Lupus Treatment? We call it systemic lupus erythematosus (SLE), but are we really treating one disease? Increasingly, I wonder whether grouping biologically distinct patients under one diagnosis is limiting https://t.co/30MGwIRUgO

Cardiovascular Risk in Rheumatoid Arthritis What is the link between cardiovascular risk and dementia? In abstract 1454, Michelle Allen and colleagues at Mayo Clinic studied 2,483 adults with incident RA diagnosed between 1980 and 2019. Patients were followed for Alzheimer’s https://t.co/JaITrlZXIt

🔎Long-term malignancy risk remains an important consideration in RA treatment See the SELECT trial program 5-year malignancy risk data for a JAKi and TNFi in RA, including in high CV-risk patients: https://t.co/1PBrCKLRan Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/hxzGpxWW0s

ACR 2026 – Day 2 Report https://t.co/H5aJMSwHwk https://t.co/gzGSaA9czB

Are GLP-1s Doing More Than Shrinking Waistlines in PsA? In abstract #0373, Pankti Mehta and colleagues examined patients from a longitudinal PsA cohort who initiated GLP-1 receptor agonist or dual GIP/GLP-1 therapy and compared them with matched controls. Baseline body mass https://t.co/FGCszLnS4N

📢 "We can't have a one-size-fits-all approach" – Dr. Saakshi Khattri Hear Dr. Khattri and Lindsay Tom, PA-C, explore the latest IL-23i and JAKi data and how it impacts their PsA treatment decisions. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/MOBlwXCFuu https://t.co/2pHRO1SQCS

Scary IPAF IPAF describes patients who have ILD plus clinical, serologic, or morphologic features of autoimmunity but who do not meet criteria for a defined connective tissue disease. The 2015 ERS/ATS criteria proposed IPAF as a research classification, not a distinct disease, https://t.co/v3ir4IHia7

Beyond Joint Inflammation: Does Early RA Control Prevent Chronic Pain and Fatigue? Could the therapeutic window of opportunity in rheumatoid arthritis extend beyond preventing structural damage to preventing chronic pain, fatigue, and neuroimmune complications? This is the https://t.co/WVSjwIHOAM

Might stem cells actually work in knee OA?? Possibly, only the right combo 🇰🇷 OSCA: OS (allo mesenchymal stem cells) + CAM (cartilage acellular matrix) anti-inflamm, structural, pain ph2a impressive signal over placebo & maybe tissue repair, benefit out to 5y? #ACR26 @RheumNow https://t.co/PU3MUqxH7Q

It's like HCQ on steroids (metaphorical not literal, & anabolic not glucocorticoid) TLR7/8 targeting in SLE (IFN-I, GC resistance, organ damage) ph2: massive signal in primary, secondaries all hit, IFN-I down from w2, safety good what a time for lupus ABSTLB23 #ACR26 @RheumNow https://t.co/mhntxC4aT4

Is 60-40-20 broken? RA trial rule of thumb: roughly 60%-40%-20% for ACR20-50-70 girocitinib (JAK1/Tyk2) vs tofacitinib ACR20: 91% vs 75% ACR50: 73% vs 49% ACR70: 44% vs 25% there will be debate (all in China, tofa exposure) but what a meeting for H2H ABSTLB21 #ACR26 @RheumNow https://t.co/SmOCzqqxFg